Trial Profile
A Multi-Center, Phase 1, Open-Label Evaluation Of The Effect Of PF-00547659 (Anti Madcam Monoclonal Antibody) On Cerebrospinal Fluid (CSF) Lymphocytes In Volunteers With Crohns Disease Or Ulcerative Colitis Who Are Anti-TNFInadequate Responders (TOSCA)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Ontamalimab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Pharmacodynamics
- Acronyms TOSCA
- Sponsors Pfizer
- 14 Jun 2016 Results published in a Shire media release.
- 17 May 2016 Results presented at the IMMUNOLOGY 2016 American Association of Immunologists Annual Meeting
- 21 Jan 2016 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.